Newbridge Financial Services Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.1K Hold
64
﹤0.01% 759
2025
Q4
$10.9K Sell
64
-43
-40% -$6.59K ﹤0.01% 767
2025
Q3
$14.1K Sell
107
-185
-63% -$22.2K ﹤0.01% 826
2025
Q2
$31K Hold
292
0.01% 608
2025
Q1
$36.3K Sell
292
-176
-38% -$23K 0.01% 435
2024
Q4
$57.6K Hold
468
0.01% 373
2024
Q3
$52.1K Hold
468
0.02% 249
2024
Q2
$50K Hold
468
0.02% 371
2024
Q1
$56.4K Hold
468
0.02% 372
2023
Q4
$57.6K Buy
468
+336
+255% +$41.9K 0.03% 364
2023
Q3
$17.1K Hold
132
0.01% 680
2023
Q2
$16.4K Hold
132
0.01% 751
2023
Q1
$19.3K Hold
132
0.01% 737
2022
Q4
$21K Hold
132
0.01% 707
2022
Q3
$18K Hold
132
0.01% 726
2022
Q2
$21K Hold
132
0.01% 643
2022
Q1
$21K Hold
132
0.01% 718
2021
Q4
$17K Sell
132
-6
-4% -$789 0.01% 778
2021
Q3
$18K Buy
138
+6
+5% +$907 0.01% 693
2021
Q2
$23K Buy
132
+116
+725% +$20.1K 0.01% 735
2021
Q1
$3K Buy
+16
New +$2.63K ﹤0.01% 1123

Other funds holding JAZZ

Newbridge Financial Services Group's JAZZ Position: Q1 2026 in Review

Newbridge Financial Services Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 64 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Newbridge Financial Services Group first reported a position in JAZZ in Q1 2021 and has held it in 21 quarters since. The position peaked at $57.6K in Q4 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Newbridge Financial Services Group held 64 shares of Jazz Pharmaceuticals worth $12.1K as of Q1 2026.
  • Newbridge Financial Services Group left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #759 holding.
  • Newbridge Financial Services Group first reported a position in Jazz Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Newbridge Financial Services Group's Jazz Pharmaceuticals position peaked at $57.6K in Q4 2024.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.